Tags

Type your tag names separated by a space and hit enter

Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies.
Cancer Res. 1988 Mar 01; 48(5):1361-6.CR

Abstract

A variety of malignancies have been associated with the presence of human chorionic gonadotropin, hCG, its subunits, and fragments of its beta-subunit in blood and urine. The usefulness of these hCG-related tumor markers in nontrophoblastic malignancies has been inhibited by inadequate assay techniques. In order to achieve the required sensitivity and specificity, concentration steps and other procedures to remove cross-reacting human luteinizing hormone were necessary. In addition, the coexistence of a fragment of the hCG-beta or beta human luteinizing hormone subunit contributes to significant errors of measurement in urine. The importance of the hCG-beta fragment as a potential tumor marker has been recognized previously but no method was available to measure this antigen readily. We report here the development of a series of radioimmunometric, two-site assays which will accurately measure hCG, hCG-beta subunit, and the beta-subunit fragment directly in small volumes of unprocessed urine. These assays are highly specific, extremely sensitive, and not labor intensive since they employ microtiter plate procedures. Application of these assays to urine samples from patients with gynecological malignancies indicated that over 50% of all patients tested excreted the hCG-beta fragment in their urine. Also, this fragment comprised more than 50% of the moles of hCG immunoreactive components present in the specimens that were positive for hCG. This cancer marker is also demonstrable in trophoblastic malignant states such as choriocarcinoma in which the low molecular weight fragment can also be visualized directly by immunoblotting procedures. We conclude that a search for hCG immunoreactivity in the urine of patients with malignancies will be improved by the inclusion of accurate measurements of the prominent quantities of the beta fragment excreted by these individuals.

Authors+Show Affiliations

Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York 10032.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

2449279

Citation

O'Connor, J F., et al. "Development of Highly Sensitive Immunoassays to Measure Human Chorionic Gonadotropin, Its Beta-subunit, and Beta Core Fragment in the Urine: Application to Malignancies." Cancer Research, vol. 48, no. 5, 1988, pp. 1361-6.
O'Connor JF, Schlatterer JP, Birken S, et al. Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies. Cancer Res. 1988;48(5):1361-6.
O'Connor, J. F., Schlatterer, J. P., Birken, S., Krichevsky, A., Armstrong, E. G., McMahon, D., & Canfield, R. E. (1988). Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies. Cancer Research, 48(5), 1361-6.
O'Connor JF, et al. Development of Highly Sensitive Immunoassays to Measure Human Chorionic Gonadotropin, Its Beta-subunit, and Beta Core Fragment in the Urine: Application to Malignancies. Cancer Res. 1988 Mar 1;48(5):1361-6. PubMed PMID: 2449279.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies. AU - O'Connor,J F, AU - Schlatterer,J P, AU - Birken,S, AU - Krichevsky,A, AU - Armstrong,E G, AU - McMahon,D, AU - Canfield,R E, PY - 1988/3/1/pubmed PY - 1988/3/1/medline PY - 1988/3/1/entrez SP - 1361 EP - 6 JF - Cancer research JO - Cancer Res VL - 48 IS - 5 N2 - A variety of malignancies have been associated with the presence of human chorionic gonadotropin, hCG, its subunits, and fragments of its beta-subunit in blood and urine. The usefulness of these hCG-related tumor markers in nontrophoblastic malignancies has been inhibited by inadequate assay techniques. In order to achieve the required sensitivity and specificity, concentration steps and other procedures to remove cross-reacting human luteinizing hormone were necessary. In addition, the coexistence of a fragment of the hCG-beta or beta human luteinizing hormone subunit contributes to significant errors of measurement in urine. The importance of the hCG-beta fragment as a potential tumor marker has been recognized previously but no method was available to measure this antigen readily. We report here the development of a series of radioimmunometric, two-site assays which will accurately measure hCG, hCG-beta subunit, and the beta-subunit fragment directly in small volumes of unprocessed urine. These assays are highly specific, extremely sensitive, and not labor intensive since they employ microtiter plate procedures. Application of these assays to urine samples from patients with gynecological malignancies indicated that over 50% of all patients tested excreted the hCG-beta fragment in their urine. Also, this fragment comprised more than 50% of the moles of hCG immunoreactive components present in the specimens that were positive for hCG. This cancer marker is also demonstrable in trophoblastic malignant states such as choriocarcinoma in which the low molecular weight fragment can also be visualized directly by immunoblotting procedures. We conclude that a search for hCG immunoreactivity in the urine of patients with malignancies will be improved by the inclusion of accurate measurements of the prominent quantities of the beta fragment excreted by these individuals. SN - 0008-5472 UR - https://www.unboundmedicine.com/medline/citation/2449279/Development_of_highly_sensitive_immunoassays_to_measure_human_chorionic_gonadotropin_its_beta_subunit_and_beta_core_fragment_in_the_urine:_application_to_malignancies_ L2 - http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=2449279 DB - PRIME DP - Unbound Medicine ER -